Last Updated : November 21, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
ravulizumab (Ultomiris)
Therapeutic Area: Generalized Myasthenia Gravis
Draft recommendations posted for stakeholder feedback: November 21, 2024
End of feedback period: 05 December , 2024
Draft Recommendation
spesolimab (Spevigo)
Therapeutic Area: generalized pustular psoriasis (GPP)
Draft recommendations posted for stakeholder feedback: November 14, 2024
End of feedback period: November 28, 2024
Draft Recommendation
ferric carboxymaltose (Ferinject)
Therapeutic Area: Iron deficiency anemia
Draft recommendations posted for stakeholder feedback: November 14, 2024
End of feedback period: November 28, 2024
Draft Recommendation
exagamglogene autotemcel (Casgevy)
Therapeutic Area: Transfusion-dependent β-thalassemia
Draft recommendations posted for stakeholder feedback: November 14, 2024
End of feedback period: November 28, 2024
Draft Recommendation
exagamglogene autotemcel (Casgevy)
Therapeutic Area: Sickle cell disease (SCD)
Draft recommendations posted for stakeholder feedback: November 14, 2024
End of feedback period: November 28, 2024
Draft Recommendation
ferric carboxymaltose (Ferinject )
Therapeutic Area: Iron deficiency in adult patients with heart failure
Draft recommendations posted for stakeholder feedback: November 14, 2024
End of feedback period: November 28, 2024
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area:
Pompe disease
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Metastatic osteosarcoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Primary biliary cholangitis (PBC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Cholangiocarcinoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Pediatric low grade glioma (ped LGG)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
advanced renal cell carcinoma (RCC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
advanced or metastatic
malignant pleural mesothelioma (MPM)
malignant pleural mesothelioma (MPM)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
large B-cell lymphoma (LBCL)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Head and neck cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Prostate cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Last Updated : November 21, 2024